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To investigate the potential role of vitamin or mineral supplementation on the risk of head and neck cancer (HNC), we
analyzed individual-level pooled data from 12 case–control studies (7,002 HNC cases and 8,383 controls) participating in the
International Head and Neck Cancer Epidemiology consortium. There were a total of 2,028 oral cavity cancer, 2,465
pharyngeal cancer, 874 unspecified oral/pharynx cancer, 1,329 laryngeal cancer and 306 overlapping HNC cases. Odds ratios
(OR) and 95% confidence intervals (CIs) for self reported ever use of any vitamins, multivitamins, vitamin A, vitamin C, vitamin
E, and calcium, beta-carotene, iron, selenium and zinc supplements were assessed. We further examined frequency, duration
and cumulative exposure of each vitamin or mineral when possible and stratified by smoking and drinking status. All ORs
were adjusted for age, sex, race/ethnicity, study center, education level, pack-years of smoking, frequency of alcohol drinking
and fruit/vegetable intake. A decreased risk of HNC was observed with ever use of vitamin C (OR 5 0.76, 95% CI 5 0.59–
0.96) and with ever use of calcium supplement (OR 5 0.64, 95% CI 5 0.42–0.97). The inverse association with HNC risk was
also observed for 10 or more years of vitamin C use (OR 5 0.72, 95% CI 5 0.54–0.97) and more than 365 tablets of
cumulative calcium intake (OR 5 0.36, 95% CI 5 0.16–0.83), but linear trends were not observed for the frequency or
duration of any supplement intake. We did not observe any strong associations between vitamin or mineral supplement intake
and the risk of HNC.
Head and neck cancer (HNC) includes cancers originating in
the oral cavity, the oropharynx, the hypopharynx and the lar-
ynx. Worldwide, more than half a million HNC cases and
over 300,000 deaths due to HNC are estimated to occur each
year.1 Tobacco smoking and alcohol consumption are the
predominant risk factors for HNC,2,3 but the role of diet has
been recognized. Increased fruit and vegetable consumption
has been repeatedly shown to be associated with a reduced
risk of HNC.4–6 However, the mechanisms underlying these
associations are complex. There are a large number of com-
pounds in plant foods that may influence the risk of cancer,
including both micronutrients for normal metabolism and
other bioactive compounds with unknown metabolic signifi-
cance. Therefore, whether dietary supplements containing
micronutrients found in plant foods would be effective che-
mopreventive agents is of considerable public health interest.
Numerous in vitro studies and animal studies have sug-
gested favorable effects of several vitamins and minerals on
angiogenesis, immunity, cell differentiation, proliferation and
apoptosis.7–9 In epidemiologic studies, the precise nature and
magnitude of the inverse relationships between multivitamin
and mineral supplements and the risk of HNC, however,
have not been clearly established because of inconsistent
results.10–20 In the early 1990s, case–control studies in the US
suggested that vitamin E and vitamin C supplement intake
was inversely associated with oral cavity and pharyngeal can-
cers.13,14 Recently published meta-analysis of randomized tri-
als suggest no association between cancer and vitamin or
mineral supplement intake.19–23 In a large randomized con-
trolled trial, supplementation with alpha-tocopheryl acetate
and beta-carotene were not associated with upper aerodiges-
tive tract cancer incidence; however, a protective effect was
suggested for early stage laryngeal cancers.11The results from
the three secondary prevention trials for HNC, beta-carotene
supplement had no significant effect for second primary
HNC risk.15–17 Therefore, this large pooled analysis was con-
ducted to investigate the potential role of vitamin or mineral
supplementation in the development of HNC.
We analyze pooled data from the International Head and
Neck Cancer Epidemiology (INHANCE) Consortium (http://
inhance.iarc.fr) that was established in 2004 based on the col-
laboration of research groups leading large, molecular epide-
miology studies of HNC. The primary goal of the consortium
is to explore potential risk factors of HNC that are difficult
to evaluate in individual studies.
Material and Methods
Study subjects
Within version 1.3 of the INHANCE consortium pooled data
set, 12 case–control studies from Europe, Latin America and
the United States with information on vitamin supplementa-
tion included data on 7,085 HNC cases and 8,491 con-
trols.24–33 In this current analysis, we excluded the India cen-
ter (576 cases and 582 controls), but not the other centers
from the IARC multicenter study because information on
vitamin supplementation was not available in the India center
questionnaire. We also excluded 169 cases and 43 controls
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with the vitamin supplementation questionnaire. Finally, sub-
jects with missing data on age, sex or race/ethnicity and cases
with missing information on the site of origin of their cancer
were excluded (87 cases and 108 controls). Thus, the data for
this analysis included 7,002 HNC cases and 8,383 controls.
Characteristics of the individual studies in the consortium
are provided in Supporting Information Table 1. Most of the
studies were hospital-based case–control studies, and in most
studies, the control subjects were frequency matched to the
case subjects on age, sex and additional factors (such as study
center, hospital and race/ethnicity). Interviews in all studies
were conducted face-to-face. Written informed consent was
obtained from study subjects, and the investigations were
approved by institutional review boards at each of the insti-
tutes involved. Questionnaires were collected from the indi-
vidual studies to assess the comparability of the data and
wording of interview questions. Each data item was checked
for illogical or missing values. Queries were sent to investiga-
tors and inconsistencies were resolved.
Cases included patients with invasive tumors of the oral
cavity, oropharynx, hypopharynx, oral cavity or pharynx not
otherwise specified, larynx or HNC unspecified as defined
previously.34 Cancers of salivary gland (International Classifi-
cation of Diseases for Oncology version 2 C07-C08) were
excluded from our analysis because of the different etiology
from other HNC.35 Studies provided tumor site data using ei-
ther the International Classification of Diseases for Oncology
version 2 or International Classification of Diseases, Ninth or
Tenth Edition. In the overall dataset, there were a total of
2,028 oral cases, 2,465 pharyngeal cases (496 hypopharynx
and 1,969 oropharynx), 874 unspecified oral/pharynx cases,
Table 1. Demographic characteristics of the head and neck cases
and controls
Demographic
characteristics Cases (%) Controls (%)
Total 7002 8383
Study
France 323 4.61 234 2.79
New York Multicenter 497 7.10 271 3.23
Seattle, WA 191 2.73 400 4.77
North Carolina 180 2.57 202 2.41
Tampa, FL 207 2.96 897 10.70
Los Angeles, CA 417 5.96 1005 11.99
Puerto Rico 350 5.00 521 6.21
Latin America 2191 31.29 1706 20.35
IARC Multicenter 983 14.04 1094 13.05
Boston 415 5.93 616 7.35




134 1.91 169 2.02
Age
<40 303 4.33 500 5.96
40_ <45 403 5.76 597 7.12
45_ <50 760 10.85 893 10.65
50_ <55 996 14.22 1347 16.07
55_ <60 1259 17.98 1455 17.36
60_ <65 1117 15.95 1244 14.84
65_ <70 950 13.57 1034 12.33
70_ <75 707 10.10 724 8.64
75 507 7.24 589 7.03
p for v2test <0.0001
Sex
Men 5392 77.01 5791 69.08
Women 1610 22.99 2592 30.92
P for v2test <0.0001
Race/Ethnicity
Nonhispanic white 3922 56.01 5406 64.49
Black 557 7.95 659 7.86
Hispanic/Latino 156 2.23 359 4.28
Asian/Pacific islanders 37 0.53 72 0.86
Others 139 1.99 181 2.16
Latin Americans1 2191 31.29 1706 20.35
P for v2test <0.0001
Education
None 139 2.18 129 1.63
<Junior high school 2444 38.38 2073 26.17
Some high school 1185 18.61 1117 14.10
High school graduate 728 11.43 960 12.12
Table 1. Demographic characteristics of the head and neck cases
and controls (Continued)
Demographic
characteristics Cases (%) Controls (%)
Vocational, some
college
1224 19.22 2042 25.78
College 648 10.18 1601 20.21
Missing 634 461
P for v2test <0.0001
HNC subtype









1Information on ethnicity was not collected in the Latin America study.
We organized subjects as ‘‘Latin American.’’ We adjusted for study
center in all logistic regression models as a proxy variable for race/
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1,329 laryngeal cases and 306 overlapping head and neck
cases.
In the 12 individual studies, each study subject was asked
whether he or she had taken any vitamins or minerals. The
definitions for ever use of vitamin or mineral supplements
were: at least once a week for a year (New York multicenter
and Tampa studies), at least once a week (Seattle study), at
least once a month (Los Angeles study), on a regular basis
for 6 months or longer (US multicenter study), on a regular
basis (Puerto Rico, France, Boston, Memorial Sloan-Kettering
Cancer Center (MSKCC) studies), before 1 year ago (North
Carolina study) and in the last 2 years (IARC multicenter
and Latin America studies). Variables on the type of vitamin
supplementation were available in nine studies (New York
multicenter, Seattle, North Carolina, Tampa, Los Angeles,
Puerto Rico, Boston, MSKCC and US multicenter studies).
Variables on the frequency of the type of vitamin supplemen-
tation were available in four studies (Seattle, Los Angeles, US
multicenter and MSKCC studies). Variables on duration of
vitamin supplementation were available in eight studies
(France, New York multicenter, North Carolina, Tampa, Los
Angeles, Puerto Rico, Boston and US multicenter studies).
The lifetime number of tablets of vitamin supplementation
was calculated based on the number of tablets per week or
day and duration reported to estimate the cumulative and
daily consumption in four studies (New York multicenter,
Tampa, North Carolina and Puerto Rico studies). In short,
for any vitamin and mineral supplement intake, three ques-
tions were included in the France, Latin America and IARC
studies; ten questions were included in Seattle study; 15 ques-
tions were included in the MSKCC (14) and Tampa (16)
studies; and more than 20 questions were included in New
York multicenter (21), Puerto Rico (24), North Carolina (25),
Los Angeles (27), US multicenter (28) and Boston (32).
Variables on pack-years of tobacco smoking and the fre-
quency of alcohol drinking were available in all studies. The
detailed description on the method used for pooling data on
smoking and alcohol across different studies is provided in a
previous paper.34 Variables on dietary information included
overall vegetables and fruit intake in quartiles based on cen-
ter-specific controls.
Statistical methods
The association between HNC risk and vitamin supplementa-
tion was assessed by estimating odds ratios (ORs) and 95%
confidence intervals (CIs) using unconditional logistic regres-
sion models for each case–control study. The model included
age, sex, education, race/ethnicity, pack-years of smoking
(continuous), the frequency of alcohol drinking (continuous)
and vegetable and fruit intake (quartiles of center-specific
controls) to adjust to potential confounders. To calculate the
summary estimates of association, the study-specific estimates
were included in a two-stage random-effects logistic regres-
sion model with the maximum likelihood method, which
allows for unexplained sources of heterogeneity between
studies.36 Pooled ORs were also estimated with a fixed-effects
logistic regression models, adjusted for all the factors men-
tioned before and study center.
For subjects missing information on education level (634
cases and 461 controls), we applied multiple imputation with
the PROC MI procedure in SAS. We assumed that the edu-
cation data were missing at random, i.e., whether or not edu-
cation was missing did not depend on any other unobserved
or missing values.37 We used the logistic regression model38
to predict education level using age, sex, race/ethnicity, study
center and case/control status as the covariates within each
of the geographic region.
We tested for heterogeneity between the study-specific
ORs by conducting the likelihood ratio test, for the head and
neck combined and for each of the subsites, by testing the
difference between the log likelihood of a model with the
product terms between study and the variable of interest, and
that of a model with no such product terms, based on a X2
distribution with a df one less than the number of studies. If
any heterogeneity was detected, we reported the random-
effects estimates and examined whether the results from the
two-stage random-effects model and the fixed-effects logistic
regression model were comparable in magnitude of effect.
Fixed-effects estimates are reported for all other models. We
also conducted meta-regression analysis between studies,
adjusting for some potential sources of heterogeneity, includ-
ing case source(hospital vs. cancer registry), year of study
(<¼1990s vs. >¼2000s), geographic location of the study
(Europe, North America vs. South/central America) and sam-
ple size(<400 vs. >400 cases). We also conducted influence
analysis, where each study was excluded one at a time to
assure that the statistical significance and magnitude of the
overall summary estimate was not dependent on any one
study.
Results
Characteristics of studies and subjects
Selected demographic characteristics of cases and controls are
shown in Table 1. The largest number of cases and controls
were from the Latin America study (2,191 cases/1,706 con-
trols), followed by the US multicenter study (1,114 cases/
1,268 controls). There was a predominance of male cases
(77%). The distributions of age, race/ethnicity and educa-
tional level were different between case and control groups.
Ever use of vitamin or mineral supplement intake
Table 2 presents the ORs of HNC according to select vitamin
supplements. Ever use of any vitamin supplement was
reported by 2,448 cases (37.6%) and 3,921 controls (48.3%),
but not associated with the risk of HNC. For individual vita-
min supplements, a decreased risk of HNC was observed
with ever use of vitamin C (OR ¼ 0.76, 95% CI 0.59–0.96)
and with ever use of calcium supplements (OR ¼ 0.64, 95%
CI 0.42–0.97) after adjustment for age, sex, race/ethnicity,
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Table 2. Vitamin or mineral supplement use and risk of head and neck cancer, INHANCE pooled
analysis
Cases/controls OR1 (95% CI) OR2 (95% CI)
Any vitamins3
Never 4016/4139 1.00 1.00




Never 1650/2702 1.00 1.00




Never 2861/4772 1.00 1.00




Never 2449/3787 1.00 1.00




Never 2574/3930 1.00 1.00




Never 1709/3164 1.00 1.00




Never 1435/2406 1.00 1.00




Never 2445/3488 1.00 1.00




Never 1100/1914 1.00 1.00
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frequency of alcohol drinking and fruit/vegetable intake. The
inverse association with calcium supplement use persisted af-
ter adjustment for ever use of other vitamins (OR ¼ 0.67,
95% CI 0.48–0.95). The ORs for vitamin C (OR ¼ 0.75, 95%
CI 0.55–0.95) did not change substantially when the analysis
was restricted to the American studies (including Seattle,
North Carolina, Tampa, Los Angeles, Puerto Rico, Boston,
US multicenter and MSKCC studies; data not shown in the
table).
Figures 1 and 2 show the study specific estimates for vita-
min C and calcium supplements. The point estimates ranged
between 0.60 and 1.24 for vitamin C and between 0.14 and
0.94 for calcium. For vitamin C, in 2 out of 7 studies the OR
was above unity (Los Angeles and Puerto Rico). For calcium,
ORs of all studies were below unity.
Heterogeneity was detected for the overall effect of vita-
min C and calcium supplements and in a few strata. The
random effect estimates, however, did not differ substantially
Table 2. Vitamin or mineral supplement use and risk of head and neck cancer, INHANCE pooled
analysis (Continued)
Cases/controls OR1 (95% CI) OR2 (95% CI)
pheterogeneity 0.73 0.74
Zinc4
Never 1080/1860 1.00 1.00
Ever 55/17 0.88(0.34–2.26) 0.88(0.55–1.43)
Missing 11/15
pheterogeneity 0.74 0.72
1Odds ratio adjusted for age, sex, race/ethnicity, study center, educational level, pack-years of smoking
(continuous), the frequency of alcohol drinking (continuous) and vegetable and fruit intake (quartiles of
center-specific controls). 2Additionally adjusted for other vitamins (Multiple vitamins, vitamin A, vitamin C
and vitamin E). 3New York study was not included in the model a; France, New York, Latin America and
IARC studies were not included in the model b. So, in model b, there were 1,492 cases and 2,098 controls
with never use of any vitamin supplementation; and 1,499 cases and 2,955 controls with the ever use of
any vitamin supplementation. 4Multiple vitamins, vitamin A, vitamin C and vitamin E do not include France,
New York, Latin America, MSKCC and IARC studies; calcium does not include France, New York, Latin America,
IARC, MSKCC and US multicenter studies; selenium and zinc include North Carolina, Los Angeles, Boston and
MSKCC studies; iron includes North Carolina, Los Angeles, Puerto Rico, Boston, US multicenter and MSKCC
studies; beta-carotene includes North Carolina, Los Angeles, Puerto Rico, Boston and MSKCC studies.
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from the fixed effect ones, although the CIs were wider.
Meta-regression was conducted for the sources of heterogene-
ity between studies. The potential sources included the case
source (hospital vs. cancer registry), year of study (1990s vs.
2000s), geographic location of the study (Europe, North
America vs. South/central America) and sample size (<400
vs. >400 cases). The results showed that the geographic loca-
tion of the study was the possible explanation for the hetero-
geneity of vitamin C supplement (p ¼ 0.047). There did not
appear to be any associations between HNC risk and ever
use of multiple vitamins, vitamin A, beta-carotene, iron, sele-
nium or zinc.
When the result was analyzed by gender, we did not
observe any difference in the results stratified by gender. For
calcium, the borderline protective effect was also observed for
calcium supplement among female subjects (OR ¼ 0.49,
95%CI ¼ 0.24–1.00), and there was no significant association
among male subjects (OR ¼ 0.77, 95%CI ¼ 0.55–1.09).
The analysis was further stratified by cancer subsite (Sup-
porting Information Table 2). There was no difference in the
reduction of risk associated with any vitamins, multiple vita-
mins, vitamin A, vitamin C, vitamin E and calcium supple-
ment use by site of oral cavity, pharynx and larynx cancer. A
27% reduction in risk of oral cavity cancer was observed for
vitamin E supplement use (OR ¼ 0.73, 95% CI ¼ 0.56–0.96).
Frequency, duration and cumulative consumption of
vitamin or mineral supplement intake
Table 3 shows the association between HNC risk and fre-
quency of various vitamins and mineral supplements. High
frequency (7–13 tablets/week) of Vitamin E intake was asso-
ciated with a decreased HNC risk (OR ¼ 0.61, 95% CI ¼
0.37–0.98), but the association was not significant after the
adjustment of dietary vitamin E intake (OR ¼ 0.59, 95% CI
¼ 0.22–1.61). For other vitamin or mineral supplement
intake, no significant association was observed between the
frequency of vitamin or mineral supplements and HNC risk
in this pooled analysis.
We next examined whether there was a dose–response
relationship between HNC risk and the years of supplement
use (Table 4). Vitamin C supplementation for 10 or more
years was associated with a reduced risk of HNC (OR ¼
0.72, 95% CI 0.54–0.97). However, statistical evidence of a
dose–response relationship was not observed (p-trend ¼
0.46), and the associations did not persist after adjustment
for other vitamins. The durations of other individual vitamin
or mineral supplements were not significantly associated with
risk of HNC.
We also explored dose–response relations for multiple
vitamins, vitamin C, vitamin E and calcium, by cumulative
consumption. Calcium supplement was associated inversely
with the risk of HNC regardless of cumulative consumption
level (OR for cumulative calcium <¼365 tablets ¼ 0.26,
95% CI ¼ 0.07–0.94; OR for cumulative calcium >365 tab-
lets ¼ 0.36, 95% CI ¼ 0.16–0.83), after adjustment for con-
founding factors, but no dose-response trend was apparent
(p-trend ¼ 0.75). There was no significant association
between HNC risk and the cumulative consumption of
other individual vitamin or mineral supplements (data not
shown).
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Table 3. Frequency of vitamin or mineral supplement use and risk of head and neck cancer, INHANCE
pooled analysis
Cases/controls OR1 (95% CI) Cases/controls OR2 (95% CI)
Any vitamins
None 896/1263 1.00 639/1103 1.00
1–6 tablets/week 84/281 0.71 (0.45–1.12) 60/266 0.64 (0.33–1.24)
7–13 tablets/week 404/686 0.79 (0.35–1.78) 207/593 0.74 (0.24–2.30)





None 972/1594 1.00 694/1415 1.00
1–6 tablets/week 52/95 1.29 (0.68–2.45) 34/88 1.14 (0.31–4.14)
7–13 tablets/week 359/549 0.97 (0.54–1.72) 181/468 0.93 (0.42–2.06)





None 1251/1821 1.00 832/1594 1.00
1–6 tablets/week 31/139 0.60 (0.31–1.17) 25/133 0.49 (0.18–1.35)
7–13 tablets/week 113/279 0.57 (0.27–1.12) 51/243 0.58 (0.30–1.12)





None 1307/1850 1.00 853/1610 1.00
1–6 tablets/week 25/145 0.59 (0.29–1.21) 22/144 0.52 (0.18–1.50)
7–13 tablets/week 76/265 0.61 (0.37–0.98) 43/237 0.59 (0.22–1.61)





None 1369/2029 1.00 899/1773 1.00
1–6 tablets/week 8/83 0.37 (0.10–1.44) 6/82 0.38 (0.14–1.01)
7–13 tablets/week 32/124 0.57 (0.28–1.17) 14/113 0.54 (0.19–1.53)




1Odds ratio adjusted for age, sex, race/ethnicity, study center, educational level, pack-years of smoking
(continuous) and the frequency of alcohol drinking (continuous). All vitamins include New York, Seattle,
North Carolina, Tampa and Puerto Rico studies. 2Odds ratio adjusted for age, sex, race/ethnicity, study
center, educational level, pack-years of smoking (continuous), the frequency of alcohol drinking
(continuous) and vegetable and fruit intake (quartiles of center-specific controls). All vitamins include
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Table 4. Duration of vitamin or mineral supplement use and risk of head and neck cancer, INHANCE
pooled analysis
Cases/controls OR1 (95% CI) Cases/controls OR2 (95% CI)
Any vitamins
None 1601/2015 1.00 1333/1832 1.00
<1 year 664/1136 0.84(0.67–1.07) 617/1094 0.84(0.60–1.16)
1–9 years 374/684 0.89(0.58–1.37) 367/676 1.01(0.72–1.43)





None 1453/2347 1.00 1453/2347 1.00
<1 year 397/688 0.87(0.68–1.11) 397/688 0.87(0.68–1.12)
1–9 years 379/641 1.00(0.82–1.22) 379/641 1.06(0.87–1.30)





None 2193/3393 1.00 2193/3393 1.00
<1 year 156/355 0.80(0.58–1.10) 156/355 0.83(0.58–1.18)
1–9 years 154/292 0.88(0.61–1.27) 154/292 0.97(0.67–1.14)





None 2297/3477 1.00 2297/3477 1.00
<1 year 129/359 0.79(0.57–1.11) 129/359 0.87(0.60–1.26)
1–9 years 131/312 0.74(0.38–1.41) 131/312 0.80(0.39–1.65)





None 1404/2658 1.00 1404/2658 1.00
<1 year 56/205 0.72(0.48–1.07) 56/205 0.71(0.47–1.07)
1–9 years 61/194 0.69(0.46–1.02) 61/194 0.71(0.47–1.07)




1Odds ratio adjusted for age, sex, race/ethnicity, study center, educational level, pack-years of smoking
(continuous), the frequency of alcohol drinking (continuous) and vegetable and fruit intake (quartiles of
center-specific controls). Any vitamins include France, North Carolina, Tampa, Los Angeles, Puerto Rico,
Boston and US multicenter studies; multiple vitamins, vitamin A, vitamin C and vitamin E include North
Carolina, Tampa, Los Angeles, Puerto Rico, Boston and US multicenter studies; calcium includes North
Carolina, Tampa, Los Angeles, Puerto Rico and Boston studies. 2Odds ratio adjusted for age, sex, race/
ethnicity, study center, educational level, pack-years of smoking (continuous), the frequency of alcohol
drinking (continuous), vegetable and fruit intake (quartiles of center-specific controls) and other vitamins
(Multiple vitamins, vitamin A, vitamin C and vitamin E). Any vitamins, multiple vitamins, vitamin A, vitamin
C and vitamin E include North Carolina, Tampa, Los Angeles, Puerto Rico, Boston and US multicenter























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Stratification by smoking and drinking status
Finally, the analysis was further stratified on smoking and
drinking status (Table 5). Among never alcohol users (212
cases and 866 controls), calcium intake was associated with
reduced HNC risk (OR ¼ 0.39, 95% CI ¼ 0.16–0.94). Ever
use of vitamin E supplement were reported by 25 cases
(17.1%) and 133 controls (18.2%) among never users of
tobacco and alcohol but not associated with the risk of HNC.
However, increased HNC risk was observed with the use of
vitamin E supplement for 1 to 9 years but the CI was so
wide (OR ¼ 5.31, 95% CI 1.43–19.76) because of the small
number of subjects with vitamin E intake of 1 to 9 years (11
cases and 37 controls). For the supplements of multiple vita-
mins and vitamin C, there was no significant association with
HNC risk when stratified by smoking or drinking status.
Discussion
This study, based on a large pooled dataset, examined associ-
ations of vitamin or mineral supplements with HNC risk.
Ever supplemental intake of vitamin C and calcium were
associated with a reduced risk of HNC in this large pooled
analysis of case–control study, but linear trends were not
observed for the frequency or duration of any supplement
intake. There did not appear to be any association between
the HNC risk and ever use of any vitamins, multiple vita-
mins, vitamin A, beta-carotene, iron, selenium and zinc.
To date, only a handful of studies evaluated the associa-
tion of supplemental vitamins and HNC. In a study focusing
on pharyngeal cancer, Rossing et al. reported increasing can-
cer risk with decreasing use of vitamin C supplement.12
Another case–control study by Barone et al., reported that
vitamin C was not associated with the risk of oral cancer.13
Vitamin C is thought to play a role in cancer chemopreven-
tion by stimulating immune function, inhibiting nitrosamine
formation, blocking the metabolic activation of carcinogens
and preventing oxidative stress.39
In our study, a 24% reduction in HNC risk was associated
with ever use of vitamin C supplement (95% CI ¼ 0.59–
0.96). The inverse association was also observed with the
long term intake of supplemental vitamin C (more than 10
years). Our results are in agreement with earlier case–control
studies. However, we note that dose–response relations were
not observed.
An inverse association between calcium supplement and
the HNC risk was detected in our pooled analysis, even after
adjustment for fruit and vegetable intake and other potential
confounding factors. Cumulative calcium intake was also sig-
nificantly associated with HNC risk. When stratified on
smoking and drinking status, the significant association was
stronger among never alcohol users. The finding may be
explained by the fact that calcium is required for optimal ac-
tivity of vitamin D and has been found to participate in regu-
lating apoptosis, cell proliferation and differentiation.40 In
animal and epidemiological studies, calcium intake has been
suggested to have protective effects against many cancer
types, including colorectal,41 breast,42 endometrial,43 prostate
and ovarian.40,41 However in our study, there was no dose–
response relationship between calcium supplement and the
risk of HNC.
Vitamin E is a strong intracellular antioxidant,44 which
has been shown to confer a cancer-inhibiting effect in animal
studies.45 Topical application of this nutrient has been
reported to inhibit the development of tumors in the hamster
buccal pouch.46 Lower serum levels of alpha-tocopherol were
related to a low oral cancer risk in some epidemiological
studies.47,48 Two case–control studies also provide modest
evidence for an inverse association between vitamin E supple-
ments and oral and pharyngeal cancers.12,13 However, results
from systematic review and meta-analysis do not provide
support for vitamin E supplementation on the reduced risk
of HNC.11,20 In addition, Bairati et al. found vitamin E sup-
plementation statistically significantly increased the risk of
second primary cancers among HNC patients in a multicen-
ter, double-blind, placebo-controlled, randomized chemopre-
vention trial.17,18 In our pooled analysis, the high frequency
of vitamin E intake was associated with a reduced the risk of
HNC, especially oral cancer. However, increased HNC risk
was observed with the vitamin E supplement for 1 to 9 years
use, although the CI was wide.
There did not appear to be any association with HNC risk
and other vitamin or mineral supplements in our study, such
as beta-carotene, selenium, iron and zinc. In a large random-
ized controlled trial, beta-carotene was observed to possibly
be protective against early stage laryngeal cancer.11 However,
the results from the three prevention trials for HNC, beta-
carotene supplement had no significant effect for second pri-
mary risk among HNC patients.15–17 Systematic reviews have
reported that beta-carotene might increase overall mortality
and cardiovascular mortality.20–23 Selenium given singly or in
combination with other supplements seemed to significantly
decrease mortality.22,49 However, few studies have investi-
gated the relation of mineral supplements and HNC. One
possible explanation for the null associations in our study is
the low prevalence of use of individual supplements.
In this analysis, there was significant heterogeneity
between studies for some vitamins, such as vitamin C. Given
the different characteristics of the various populations, varia-
tion in assessment in exposure and the study design, a degree
of heterogeneity across studies is to be expected. Meta-regres-
sion analysis showed that the geographic location of the stud-
ies might explain the source for the heterogeneity across
studies. It is possible that the prevalence of susceptibility
genes varies in different populations. For example, for vita-
min C supplement, the five studies for which the point esti-
mate was below 1 were from North America. Another expla-
nation for the source of heterogeneity is that the case subtype
distribution may differ by geographic location or hospital
type/specialty. A few studies did not include cases of the lar-
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Rico and IARC studies) since all of the studies recruited eligi-
ble HNC patients sequentially. Moreover, the different types
of questions and the different number of questions were
across the studies.
There are several limitations in our pooled analysis. A
potential limitation with regards to pooling data on ever use
of vitamin or mineral supplements is the difference of defini-
tion of ever use. Accordingly, individuals with low vitamin or
mineral supplement use might have been categorized as a
‘‘never user of vitamin or mineral supplements’’ in the analy-
sis because of the wording on the questionnaires used to es-
tablish the ‘‘unexposed’’ group in the studies. The studies
with the highest thresholds for classifying an individual as
unexposed were the New York multicenter and Tampa stud-
ies (never users were defined as an individual who took any
vitamins or minerals at least once a week for a year) and the
US multicenter study (never users were defined as an individ-
ual who took any vitamins on a regular basis less than for 6
months). However, the ORs for these studies with higher
thresholds were not necessarily toward the null, if inclusion
of these minimal users had an impact on the association.
Recall bias is a potential limitation in retrospective studies
because the subjects knew their disease status when they
were interviewed. Supplemental vitamin use is not an estab-
lished protective factor specifically for HNC, especially in the
knowledge of the public at the time of the studies. Therefore,
we would expect recall bias to be minimal during the inter-
view for vitamin or mineral supplements assessment.
Another limitation is our inability to adjust for other
potential confounding factors, such as micronutrients from
dietary intake and HPV infection. We adjusted on fruit and
vegetable intake as confounding factors in our study because
most antioxidant vitamins are from fruit and vegetables.
HPV would not be expected to result in major confounding
because an association between vitamin or mineral supple-
ments and HPV infection has not been established. It would
be of interest to explore this area in the future when HPV
data may be available with a standardized measure across the
INHANCE studies.
Furthermore, although the pooled data provided large
sample size for the investigation on vitamin or mineral sup-
plements and HNC risk, the statistical power of analysis was
limited for beta-carotene, iron, selenium and zinc because the
prevalence of these supplements was low in the study popula-
tion. It was difficult to analyze the duration and frequency of
these supplements because of small sample size.
The major strength of our pooled analyses was assembly
of a very large series HNC patients and control subjects,
which allowed us to examine HNC risks in detail and to
explore differences in risks by cancer subsites, smoking and
alcohol status. To our knowledge, the estimates we present
are the most precise available for the relationship of vitamin
supplement and HNC risk. In summary, though some associ-
ations were suggested for vitamin C and calcium supplement
use, dose-response trends were not observed.
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